Home
AGIO
AGIO News

Latest Agios Pharmaceuticals Inc. (AGIO) News on September 16, 2025

Atavistik Bio Expands Leadership Team with Appointment of Susan Pandya, M.D., as Chief Medical Officer

GlobeNewswire

a day ago

Atavistik Bio Expands Leadership Team with Appointment of Susan Pandya, M.D., as Chief Medical Officer

FDA Review Delay for PYRUKYND Might Change the Case for Investing in Agios Pharmaceuticals (AGIO)

Simply Wall St.

8 days ago

FDA Review Delay for PYRUKYND Might Change the Case for Investing in Agios Pharmaceuticals (AGIO)

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

Zacks

11 days ago

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

MT Newswires

3 months ago

Agios Pharmaceuticals Insider Sold Shares Worth $627,198, According to a Recent SEC Filing

Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential

Insider Monkey

3 months ago

Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential

H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT

Insider Monkey

3 months ago

H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT

Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?

Zacks

3 months ago

Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?

Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?

Zacks

3 months ago

Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

GlobeNewswire

4 months ago

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

GlobeNewswire

4 months ago

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders

Simply Wall St.

4 months ago

Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

GlobeNewswire

4 months ago

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates

Zacks

4 months ago

Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

GlobeNewswire

4 months ago

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...

GuruFocus.com

4 months ago

Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...

MT Newswires

5 months ago

Agios Pharmaceuticals Shares Down After Q1 Net Loss Widens, Revenue Misses Estimates

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates

Zacks

5 months ago

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates

Associated Press Finance

5 months ago

Agios Pharmaceuticals: Q1 Earnings Snapshot

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire

5 months ago

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

Zacks

5 months ago

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

MT Newswires

5 months ago

BofA Adjusts Price Target on Agios Pharmaceuticals to $52 From $54, Keeps Buy Rating

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

GlobeNewswire

5 months ago

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

New Strong Sell Stocks for April 3rd

Zacks

5 months ago

New Strong Sell Stocks for April 3rd

Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar?

Zacks

6 months ago

Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar?

Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode?

Insider Monkey

6 months ago

Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode?

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

GlobeNewswire

6 months ago

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Agios to Present at Upcoming Investor Conferences

GlobeNewswire

6 months ago

Agios to Present at Upcoming Investor Conferences

Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now?

Insider Monkey

7 months ago

Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now?

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

GlobeNewswire

7 months ago

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank

TipRanks

7 months ago

Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank

Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues

Zacks

7 months ago

Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues

Agios Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

7 months ago

Agios Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...

GuruFocus.com

7 months ago

Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...

Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years

Benzinga

7 months ago

Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates

Zacks

7 months ago

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates

MT Newswires

7 months ago

Agios Pharmaceuticals' Q4 Loss Widens, Revenue Rises

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

GlobeNewswire

7 months ago

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

GlobeNewswire

7 months ago

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Agios Pharmaceuticals price target lowered to $54 from $55 at BofA

TipRanks

7 months ago

Agios Pharmaceuticals price target lowered to $54 from $55 at BofA

Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now

Insider Monkey

7 months ago

Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now

MT Newswires

7 months ago

BofA Securities Trims Price Target on Agios Pharmaceuticals to $54 From $55, Maintains Buy Rating

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

GlobeNewswire

7 months ago

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential

Insider Monkey

8 months ago

Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

GlobeNewswire

8 months ago

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia

Zacks

8 months ago

FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia

MT Newswires

8 months ago

Agios Pharmaceuticals Says FDA Accepted Supplemental New Drug Application for Pyrukynd

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

GlobeNewswire

8 months ago

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

MT Newswires

8 months ago

BofA Securities Adjusts Price Target on Agios Pharmaceuticals to $55 From $60, Maintains Buy Rating

How to Navigate the Stock and Bond Markets in 2025

The Wall Street Journal

8 months ago

How to Navigate the Stock and Bond Markets in 2025

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

GlobeNewswire

8 months ago

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

MT Newswires

9 months ago

Agios Pharmaceuticals Says Mitapivat Granted EU Orphan Drug Status for Sickle Cell Disease

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

GlobeNewswire

9 months ago

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

Here's Why Agios Stock Plummeted More Than 20% on Monday

Zacks

9 months ago

Here's Why Agios Stock Plummeted More Than 20% on Monday

Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank

TipRanks

9 months ago

Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank

MT Newswires

9 months ago

RBC Raises Price Target on Agios Pharmaceuticals to $57 From $55, Keeps Outperform Rating

Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug

Investor's Business Daily

9 months ago

Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug

MT Newswires

9 months ago

Agios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

GlobeNewswire

9 months ago

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?

Zacks

9 months ago

Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?

Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?

Zacks

9 months ago

Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?

Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios

Zacks

9 months ago

Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios

4 Medical Product Stocks to Buy From a Prospective Industry

Zacks

9 months ago

4 Medical Product Stocks to Buy From a Prospective Industry

Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?

Zacks

10 months ago

Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?

Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News

Simply Wall St.

10 months ago

Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

GlobeNewswire

10 months ago

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down

Zacks

10 months ago

AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?

Zacks

10 months ago

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?

Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

10 months ago

Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...

GuruFocus.com

a year ago

Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...

MT Newswires

a year ago

Agios Pharmaceuticals Shares Fall After Q3 Revenue Miss

Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates

Zacks

a year ago

Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates

Associated Press Finance

a year ago

Agios Pharmaceuticals: Q3 Earnings Snapshot

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

GlobeNewswire

a year ago

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

GlobeNewswire

a year ago

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

GlobeNewswire

a year ago

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

MT Newswires

a year ago

Scotiabank Initiates Agios Pharmaceuticals at Sector Outperform With $51 Price Target

MT Newswires

a year ago

Agios Pharmaceuticals' Shares Fall After Downgrade From Leerink Partners

Do Options Traders Know Something About Agios (AGIO) Stock We Don't?

Zacks

a year ago

Do Options Traders Know Something About Agios (AGIO) Stock We Don't?

MT Newswires

a year ago

Leerink Partners Downgrades Agios Pharmaceuticals to Market Perform From Outperform, Price Target is $56

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.

Investor's Business Daily

a year ago

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.

Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results

Insider Monkey

a year ago

Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

Simply Wall St.

a year ago

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer

Zacks

a year ago

FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer

Agios Pharmaceuticals’ tebapivat gains FDA orphan drug designation

Pharmaceutical Technology

a year ago

Agios Pharmaceuticals’ tebapivat gains FDA orphan drug designation

MT Newswires

a year ago

Agios Pharmaceuticals Says FDA Granted Orphan Drug Designation to Blood Disorder Drug Candidate Tebapivat

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

GlobeNewswire

a year ago

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?

Zacks

a year ago

Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

GlobeNewswire

a year ago

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

MT Newswires

a year ago

Agios Pharmaceuticals Insider Sold Shares Worth $474,140, According to a Recent SEC Filing

Agios Pharmaceuticals, Inc. (AGIO): Are Street Analysts Bullish on This Top Caligan Partner Holding Right Now?

Insider Monkey

a year ago

Agios Pharmaceuticals, Inc. (AGIO): Are Street Analysts Bullish on This Top Caligan Partner Holding Right Now?

Is Agios Pharmaceuticals, Inc. (AGIO) a Good Addition to Your Portfolio Now?

Insider Monkey

a year ago

Is Agios Pharmaceuticals, Inc. (AGIO) a Good Addition to Your Portfolio Now?

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

GlobeNewswire

a year ago

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Here's What Analysts Are Forecasting For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) After Its Second-Quarter Results

Simply Wall St.

a year ago

Here's What Analysts Are Forecasting For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) After Its Second-Quarter Results

Agios Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

a year ago

Agios Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations

AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal

Zacks

a year ago

AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's Revenue Estimates By 12%

Simply Wall St.

a year ago

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's Revenue Estimates By 12%

MT Newswires

a year ago

RBC Raises Price Target on Agios Pharmaceuticals to $55 From $53, Keeps Outperform Rating

Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides

Benzinga

a year ago

Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides

MT Newswires

a year ago

Agios Pharmaceuticals Shares Down After Q2 Results Fall Short of Market Expectations

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates

Zacks

a year ago

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates

Share on Social Networks: